AstraZeneca and Daiichi Sankyo's Enhertu Approved in EU for HER2-positive Early Breast Cancer

AstraZeneca and Daiichi Sankyo received EU approval for Enhertu (trastuzumab deruxtecan) as an adjuvant treatment for patients with HER2-positive early breast cancer who have residual disease after neoadjuvant therapy. The decision was supported by the DESTINY-Breast05 trial, which found a 53% reduction in the risk of invasive disease recurrence. The approval expands Enhertu’s use in the European market.